Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC.ALNY · Entity 3132 | Director | January 23, 2025 | January 24, 2025 |
| Syros Pharmaceuticals, Inc.SYRS · Entity 85437 | Director | June 01, 2022 | June 02, 2022 |
| Vir Biotechnology, Inc.VIR · Entity 4522 | Director | May 22, 2023 | May 24, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALNYLAM PHARMACEUTICALS, INC.
Report date January 23, 2025 · Filed January 24, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2025-01-23 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-01-23 · Exercise / conversion · Acquired 11,250 · Balance 11,250 F1: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on August 2, 2024. The 11,250 options exercised and sold by the reporting person were due to expire on June 1, 2025. Row 2 · 2025-01-23 · Sale · Disposed 11,250 · Balance 0 F1: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on August 2, 2024. The 11,250 options exercised and sold by the reporting person were due to expire on June 1, 2025. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $131.21 · Expires 2025-06-01 | Direct | 0 |
Reported balance
After 2025-01-23 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-01-23 · Exercise / conversion · Disposed 11,250 · Balance 0 F1: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on August 2, 2024. The 11,250 options exercised and sold by the reporting person were due to expire on June 1, 2025. F3: This stock option was fully vested and exercisable as of June 1, 2016. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 266,899 |
Reported balance
Holding disclosure · report date 2025-01-23 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 266,899 F2: Includes shares held by the Phillip A. Sharp Revocable Trust, of which the reporting person and his spouse are co-trustees. Also includes shares held in trust for the benefit of the reporting persons children, of which the reporting persons children and spouse are the trustees. |
Filing footnotes · ownership attribution and instrument terms
F1: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on August 2, 2024. The 11,250 options exercised and sold by the reporting person were due to expire on June 1, 2025.
F2: Includes shares held by the Phillip A. Sharp Revocable Trust, of which the reporting person and his spouse are co-trustees. Also includes shares held in trust for the benefit of the reporting persons children, of which the reporting persons children and spouse are the trustees.
F3: This stock option was fully vested and exercisable as of June 1, 2016.
Syros Pharmaceuticals, Inc.
Report date June 01, 2022 · Filed June 02, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.78 · Expires 2032-05-31 | Direct | 17,500 |
Reported balance
After 2022-06-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-01 · Grant · Acquired 17,500 · Balance 17,500 F1: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date.
Vir Biotechnology, Inc.
Report date May 22, 2023 · Filed May 24, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 121,174 |
Reported balance
After 2023-05-22 transaction · row 1
1 source rowRow 1 · 2023-05-22 · Grant · Acquired 6,027 · Balance 121,174 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.74 · Expires 2033-05-21 | Direct | 12,054 |
Reported balance
After 2023-05-22 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-05-22 · Grant · Acquired 12,054 · Balance 12,054 |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 44,444 |
Reported balance
Holding disclosure · report date 2023-05-22 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 44,444 F1: The shares are held by the Phillip A. Sharp Irrevocable Trust 11/04/08 FBO Sarah Brokaw, over which the reporting person's spouse is co-trustee. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 44,444 |
Reported balance
Holding disclosure · report date 2023-05-22 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 44,444 F2: The shares are held by the Phillip A. Sharp Irrevocable Trust 11/04/08 FBO Helena Sharp, over which the reporting person's spouse is co-trustee. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 44,444 |
Reported balance
Holding disclosure · report date 2023-05-22 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 44,444 F3: The shares are held by the Phillip A. Sharp Irrevocable Trust 11/04/08 FBO Christine Carey, over which the reporting person's spouse is co-trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares are held by the Phillip A. Sharp Irrevocable Trust 11/04/08 FBO Sarah Brokaw, over which the reporting person's spouse is co-trustee.
F2: The shares are held by the Phillip A. Sharp Irrevocable Trust 11/04/08 FBO Helena Sharp, over which the reporting person's spouse is co-trustee.
F3: The shares are held by the Phillip A. Sharp Irrevocable Trust 11/04/08 FBO Christine Carey, over which the reporting person's spouse is co-trustee.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 12, 2020 Filed Feb 13, 2020 21:06 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 30,000 | $130.00 | $3,900,000.00 |
DisclosureSEC source: 0001735276-20-000016 · edgardoc.xml · nonDerivative · entry 3 SHARP PHILLIP A · CIK 0001226295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,633 F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. Read SEC document |
| February 12, 2020 Filed Feb 13, 2020 21:06 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 15,000 | $9.14 | $137,100.00 |
DisclosureSEC source: 0001735276-20-000016 · edgardoc.xml · nonDerivative · entry 2 SHARP PHILLIP A · CIK 0001226295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,633 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. Read SEC document |
| February 12, 2020 Filed Feb 13, 2020 21:06 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 15,000 | $15.82 | $237,300.00 |
DisclosureSEC source: 0001735276-20-000016 · edgardoc.xml · nonDerivative · entry 1 SHARP PHILLIP A · CIK 0001226295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,633 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. Read SEC document |
| November 18, 2019 Filed Nov 20, 2019 21:17 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $16.43 | $0.00 |
DisclosureSEC source: 0001735276-19-000096 · edgardoc.xml · derivative · entry 6 SHARP PHILLIP A · CIK 0001226295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2019-12-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2019. The 15,000 options exercised and sold by the reporting person were due to expire on December 9, 2019. Read SEC document |
| November 18, 2019 Filed Nov 20, 2019 21:17 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 810 | $92.66 | $75,054.60 |
DisclosureSEC source: 0001735276-19-000096 · edgardoc.xml · nonDerivative · entry 4 SHARP PHILLIP A · CIK 0001226295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,633 F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2019. The 15,000 options exercised and sold by the reporting person were due to expire on December 9, 2019. F4 · price: Sale prices ranged from $92.53 to $92.74. Read SEC document |
| November 18, 2019 Filed Nov 20, 2019 21:17 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 8,631 | $91.97 | $793,793.07 |
DisclosureSEC source: 0001735276-19-000096 · edgardoc.xml · nonDerivative · entry 3 SHARP PHILLIP A · CIK 0001226295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,443 F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2019. The 15,000 options exercised and sold by the reporting person were due to expire on December 9, 2019. F3 · price: Sale prices ranged from $91.50 to $92.48. Read SEC document |
| November 18, 2019 Filed Nov 20, 2019 21:17 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 5,559 | $91.17 | $506,814.03 |
DisclosureSEC source: 0001735276-19-000096 · edgardoc.xml · nonDerivative · entry 2 SHARP PHILLIP A · CIK 0001226295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,074 F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2019. The 15,000 options exercised and sold by the reporting person were due to expire on December 9, 2019. F2 · price: Sale prices ranged from $90.50 to $91.49. Read SEC document |
| November 18, 2019 Filed Nov 20, 2019 21:17 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 15,000 | $16.43 | $246,450.00 |
DisclosureSEC source: 0001735276-19-000096 · edgardoc.xml · nonDerivative · entry 1 SHARP PHILLIP A · CIK 0001226295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,633 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2019. The 15,000 options exercised and sold by the reporting person were due to expire on December 9, 2019. Read SEC document |
| October 16, 2019 Filed Oct 18, 2019 23:53 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | ConversionSeries A-1 Convertible Preferred Stock · Derivative | 44,444 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-053663 · doc4.xml · derivative · entry 8 SHARP PHILLIP A · CIK 0001226295 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 44,444 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A-1 Convertible Preferred Stock (the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · price: Each share of the Issuer's Series A-1 Convertible Preferred Stock (the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of the Issuer's Series A-1 Convertible Preferred Stock (the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of the Issuer's Series A-1 Convertible Preferred Stock (the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F4 · ownership.nature: The shares are held by the Phillip A. Sharp Irrevocable Trust 11/04/08 FBO Christine Carey, over which the reporting person's spouse is co-trustee. Read SEC document |
| October 16, 2019 Filed Oct 18, 2019 23:53 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | ConversionSeries A-1 Convertible Preferred Stock · Derivative | 44,444 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-053663 · doc4.xml · derivative · entry 7 SHARP PHILLIP A · CIK 0001226295 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 44,444 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A-1 Convertible Preferred Stock (the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · price: Each share of the Issuer's Series A-1 Convertible Preferred Stock (the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of the Issuer's Series A-1 Convertible Preferred Stock (the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of the Issuer's Series A-1 Convertible Preferred Stock (the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F3 · ownership.nature: The shares are held by the Phillip A. Sharp Irrevocable Trust 11/04/08 FBO Helena Sharp, over which the reporting person's spouse is co-trustee. Read SEC document |
| October 16, 2019 Filed Oct 18, 2019 23:53 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | ConversionSeries A-1 Convertible Preferred Stock · Derivative | 44,444 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-053663 · doc4.xml · derivative · entry 6 SHARP PHILLIP A · CIK 0001226295 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 44,444 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A-1 Convertible Preferred Stock (the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · price: Each share of the Issuer's Series A-1 Convertible Preferred Stock (the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of the Issuer's Series A-1 Convertible Preferred Stock (the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of the Issuer's Series A-1 Convertible Preferred Stock (the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · ownership.nature: The shares are held by the Phillip A. Sharp Irrevocable Trust 11/04/08 FBO Sarah Brokaw, over which the reporting person's spouse is co-trustee. Read SEC document |
| October 16, 2019 Filed Oct 18, 2019 23:53 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | ConversionSeries A-1 Convertible Preferred Stock · Derivative | 88,888 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-053663 · doc4.xml · derivative · entry 5 SHARP PHILLIP A · CIK 0001226295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 88,888 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A-1 Convertible Preferred Stock (the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · price: Each share of the Issuer's Series A-1 Convertible Preferred Stock (the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of the Issuer's Series A-1 Convertible Preferred Stock (the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of the Issuer's Series A-1 Convertible Preferred Stock (the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. Read SEC document |
| October 16, 2019 Filed Oct 18, 2019 23:53 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | ConversionCommon Stock | 44,444 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-053663 · doc4.xml · nonDerivative · entry 4 SHARP PHILLIP A · CIK 0001226295 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 44,444 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the Issuer's Series A-1 Convertible Preferred Stock (the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F4 · ownership.nature: The shares are held by the Phillip A. Sharp Irrevocable Trust 11/04/08 FBO Christine Carey, over which the reporting person's spouse is co-trustee. Read SEC document |
| October 16, 2019 Filed Oct 18, 2019 23:53 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | ConversionCommon Stock | 44,444 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-053663 · doc4.xml · nonDerivative · entry 3 SHARP PHILLIP A · CIK 0001226295 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 44,444 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the Issuer's Series A-1 Convertible Preferred Stock (the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F3 · ownership.nature: The shares are held by the Phillip A. Sharp Irrevocable Trust 11/04/08 FBO Helena Sharp, over which the reporting person's spouse is co-trustee. Read SEC document |
| October 16, 2019 Filed Oct 18, 2019 23:53 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | ConversionCommon Stock | 44,444 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-053663 · doc4.xml · nonDerivative · entry 2 SHARP PHILLIP A · CIK 0001226295 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 44,444 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the Issuer's Series A-1 Convertible Preferred Stock (the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · ownership.nature: The shares are held by the Phillip A. Sharp Irrevocable Trust 11/04/08 FBO Sarah Brokaw, over which the reporting person's spouse is co-trustee. Read SEC document |
| October 16, 2019 Filed Oct 18, 2019 23:53 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | ConversionCommon Stock | 88,888 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-053663 · doc4.xml · nonDerivative · entry 1 SHARP PHILLIP A · CIK 0001226295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,368 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the Issuer's Series A-1 Convertible Preferred Stock (the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. Read SEC document |
| October 10, 2019 Filed Oct 11, 2019 23:43 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantStock Option (Right to Buy) · Derivative | 22,222 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0001209191-19-053067 · doc4.xml · derivative · entry 1 SHARP PHILLIP A · CIK 0001226295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,222 Underlying: Common Stock · 22,222 shares Expires 2029-10-10 F1 · derivative.exercise_date: 1/3 of the shares subject to the stock option vest and become exercisable on October 10, 2020, and the remainder vest in 24 equal monthly installments thereafter. Read SEC document |
| July 01, 2019 Filed Jul 2, 2019 20:07 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 9,000 | $0.00 Strike: $72.01 | $0.00 |
DisclosureSEC source: 0001735276-19-000067 · edgardoc.xml · derivative · entry 1 SHARP PHILIP A · CIK 0001226295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2029-06-30 Read SEC document |
| June 11, 2019 Filed Jun 12, 2019 16:16 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | GrantStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $5.60 | $0.00 |
DisclosureSEC source: 0001209191-19-036365 · doc4.xml · derivative · entry 1 SHARP PHILIP A · CIK 0001226295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2029-06-10 F1 · derivative.exercise_date: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date. Read SEC document |
| April 15, 2019 Filed Apr 17, 2019 20:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $22.09 | $0.00 |
DisclosureSEC source: 0001735276-19-000037 · edgardoc.xml · derivative · entry 7 SHARP PHILIP A · CIK 0001226295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2019-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2018. Read SEC document |
| April 15, 2019 Filed Apr 17, 2019 20:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 600 | $91.40 | $54,840.00 |
DisclosureSEC source: 0001735276-19-000037 · edgardoc.xml · nonDerivative · entry 5 SHARP PHILIP A · CIK 0001226295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,633 F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2018. F5 · price: Sale prices ranged from $91.00 to $91.86. Read SEC document |
| April 15, 2019 Filed Apr 17, 2019 20:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 400 | $89.97 | $35,988.00 |
DisclosureSEC source: 0001735276-19-000037 · edgardoc.xml · nonDerivative · entry 4 SHARP PHILIP A · CIK 0001226295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,233 F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2018. F4 · price: Sale prices ranged from $89.56 to $90.13. Read SEC document |
| April 15, 2019 Filed Apr 17, 2019 20:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 2,200 | $89.03 | $195,866.00 |
DisclosureSEC source: 0001735276-19-000037 · edgardoc.xml · nonDerivative · entry 3 SHARP PHILIP A · CIK 0001226295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,633 F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2018. F3 · price: Sale prices ranged from $88.49 to $89.43. Read SEC document |
| April 15, 2019 Filed Apr 17, 2019 20:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 11,800 | $87.86 | $1,036,748.00 |
DisclosureSEC source: 0001735276-19-000037 · edgardoc.xml · nonDerivative · entry 2 SHARP PHILIP A · CIK 0001226295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,833 F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2018. F2 · price: Sale prices ranged from $87.48 to $88.43. Read SEC document |
| April 15, 2019 Filed Apr 17, 2019 20:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 15,000 | $22.09 | $331,350.00 |
DisclosureSEC source: 0001735276-19-000037 · edgardoc.xml · nonDerivative · entry 1 SHARP PHILIP A · CIK 0001226295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,633 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2018. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 20:20 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 9,000 | $0.00 Strike: $105.26 | $0.00 |
DisclosureSEC source: 0001735276-18-000034 · edgardoc.xml · derivative · entry 1 SHARP PHILIP A · CIK 0001226295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2028-06-19 Read SEC document |
| June 14, 2018 Filed Jun 15, 2018 16:29 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | GrantStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $12.95 | $0.00 |
DisclosureSEC source: 0001179110-18-008623 · edgar.xml · derivative · entry 1 SHARP PHILIP A · CIK 0001226295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2028-06-13 F1 · derivative.exercise_date: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date. Read SEC document |
| March 13, 2018 Filed Mar 14, 2018 23:39 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $21.35 | $0.00 |
DisclosureSEC source: 0001553878-18-000021 · edgardoc.xml · derivative · entry 4 SHARP PHILIP A · CIK 0001226295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2018-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 10, 2017. Read SEC document |
| March 13, 2018 Filed Mar 14, 2018 23:39 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 15,000 | $149.00 | $2,235,000.00 |
DisclosureSEC source: 0001553878-18-000021 · edgardoc.xml · nonDerivative · entry 2 SHARP PHILIP A · CIK 0001226295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,795 F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 10, 2017. Read SEC document |
| March 13, 2018 Filed Mar 14, 2018 23:39 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 15,000 | $21.35 | $320,250.00 |
DisclosureSEC source: 0001553878-18-000021 · edgardoc.xml · nonDerivative · entry 1 SHARP PHILIP A · CIK 0001226295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,795 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 10, 2017. Read SEC document |
| March 09, 2018 Filed Mar 13, 2018 21:22 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $27.28 | $0.00 |
DisclosureSEC source: 0001325812-18-000020 · edgardoc.xml · derivative · entry 4 SHARP PHILIP A · CIK 0001226295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2018-06-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 10, 2017. Read SEC document |
| March 09, 2018 Filed Mar 13, 2018 21:22 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 15,000 | $129.00 | $1,935,000.00 |
DisclosureSEC source: 0001325812-18-000020 · edgardoc.xml · nonDerivative · entry 2 SHARP PHILIP A · CIK 0001226295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,795 F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 10, 2017. Read SEC document |
| March 09, 2018 Filed Mar 13, 2018 21:22 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 15,000 | $27.28 | $409,200.00 |
DisclosureSEC source: 0001325812-18-000020 · edgardoc.xml · nonDerivative · entry 1 SHARP PHILIP A · CIK 0001226295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,795 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 10, 2017. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 16:02 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | GrantStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $14.26 | $0.00 |
DisclosureSEC source: 0001179110-17-008895 · edgar.xml · derivative · entry 1 SHARP PHILIP A · CIK 0001226295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2027-06-07 F1 · derivative.exercise_date: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the award, with the remainder vesting in equal monthly installments until the first anniversary of the date of the award, subject to the reporting person's continued service as a director through each applicable vesting date. Read SEC document |
| June 08, 2017 Filed Sep 22, 2017 17:20 UTC Amendment | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | GrantStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $14.62 | $0.00 |
DisclosureSEC source: 0001179110-17-012631 · edgar.xml · derivative · entry 1 SHARP PHILIP A · CIK 0001226295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2027-06-07 F2 · derivative.exercise_price: This amendment to the Statement of Changes in Beneficial Ownership of Securities on Form 4 filed with the Securities and Exchange Commission on June 12, 2017 is being filed to correct a typographical error in the exercise price of the option to purchase Common Stock held by the reporting person. F1 · derivative.exercise_date: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the award, with the remainder vesting in equal monthly installments until the first anniversary of the date of the award, subject to the reporting person's continued service as a director through each applicable vesting date. Read SEC document |
| June 02, 2017 Filed Jun 6, 2017 21:02 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 11,250 | $0.00 Strike: $71.99 | $0.00 |
DisclosureSEC source: 0001553878-17-000033 · edgardoc.xml · derivative · entry 1 SHARP PHILIP A · CIK 0001226295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,250 Underlying: Common Stock · 11,250 shares Expires 2027-06-01 Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 21:32 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $31.29 | $0.00 |
DisclosureSEC source: 0001553878-17-000009 · edgardoc.xml · derivative · entry 5 SHARP PHILIP A · CIK 0001226295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2017-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2016. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 21:32 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 4,829 | $40.16 | $193,932.64 |
DisclosureSEC source: 0001553878-17-000009 · edgardoc.xml · nonDerivative · entry 3 SHARP PHILIP A · CIK 0001226295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,795 F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2016. F3 · price: Sale prices ranged from $40.10 to $40.24 Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 21:32 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 20,171 | $39.72 | $801,192.12 |
DisclosureSEC source: 0001553878-17-000009 · edgardoc.xml · nonDerivative · entry 2 SHARP PHILIP A · CIK 0001226295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,624 F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2016. F2 · price: Sale prices ranged from $39.09 to $40.08 Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 21:32 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 25,000 | $31.29 | $782,250.00 |
DisclosureSEC source: 0001553878-17-000009 · edgardoc.xml · nonDerivative · entry 1 SHARP PHILIP A · CIK 0001226295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,795 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2016. Read SEC document |
| January 25, 2017 Filed Jan 27, 2017 21:10 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $31.39 | $0.00 |
DisclosureSEC source: 0001553878-17-000007 · edgardoc.xml · derivative · entry 4 SHARP PHILIP A · CIK 0001226295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2017-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2016. Read SEC document |
| January 25, 2017 Filed Jan 27, 2017 21:10 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 15,000 | $37.95 | $569,250.00 |
DisclosureSEC source: 0001553878-17-000007 · edgardoc.xml · nonDerivative · entry 2 SHARP PHILIP A · CIK 0001226295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,795 F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2016. F2 · price: Sale prices ranged from $37.31 to $38.25 Read SEC document |
| January 25, 2017 Filed Jan 27, 2017 21:10 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 15,000 | $31.39 | $470,850.00 |
DisclosureSEC source: 0001553878-17-000007 · edgardoc.xml · nonDerivative · entry 1 SHARP PHILIP A · CIK 0001226295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,795 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2016. Read SEC document |
| January 18, 2017 Filed Jan 20, 2017 21:12 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $15.91 | $0.00 |
DisclosureSEC source: 0001553878-17-000004 · edgardoc.xml · derivative · entry 5 SHARP PHILIP A · CIK 0001226295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2017-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2016. Read SEC document |
| January 18, 2017 Filed Jan 20, 2017 21:12 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 6,200 | $38.20 | $236,840.00 |
DisclosureSEC source: 0001553878-17-000004 · edgardoc.xml · nonDerivative · entry 3 SHARP PHILIP A · CIK 0001226295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,795 F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2016. F3 · price: Sale prices ranged from $38.09 to $38.50 Read SEC document |
| January 18, 2017 Filed Jan 20, 2017 21:12 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 8,800 | $37.57 | $330,616.00 |
DisclosureSEC source: 0001553878-17-000004 · edgardoc.xml · nonDerivative · entry 2 SHARP PHILIP A · CIK 0001226295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,995 F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2016. F2 · price: Sale prices ranged from $37.07 to $38.06 Read SEC document |
| January 18, 2017 Filed Jan 20, 2017 21:12 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 15,000 | $15.91 | $238,650.00 |
DisclosureSEC source: 0001553878-17-000004 · edgardoc.xml · nonDerivative · entry 1 SHARP PHILIP A · CIK 0001226295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,795 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2016. Read SEC document |
| September 15, 2016 Filed Sep 19, 2016 06:56 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | GrantStock Option (right to buy) · Derivative | 22,000 | $0.00 Strike: $12.59 | $0.00 |
DisclosureSEC source: 0001104659-16-145304 · a4.xml · derivative · entry 1 SHARP PHILIP A · CIK 0001226295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2026-09-14 F1 · derivative.exercise_date: The option becomes exercisable as to 16.66% of the shares underlying the award on the six month anniversary of the award, with the remainder vesting in equal monthly installments of 2.77% of the shares underlying the award until the third anniversary of the date of the award, subject to Dr. Sharp's continued service as a director through each applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.